Xilio Therapeutics (XLO) director Cheryl Blanchard enters as reporting insider

Rhea-AI Filing Summary

Xilio Therapeutics, Inc. filed an initial insider ownership report for director Cheryl R. Blanchard. This Form 3 identifies her status as a director of the company but shows no reported stock transactions or derivative positions at the time of filing.

Key Terms

Form 3, director, transaction summary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

director financial

""is_director": 1"

transaction summary financial

""transactionSummary": {"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 04/16/2026 - 05:11 PM Learn about SEC filing dates

FAQ

What does this Form 3 filing for XLO show about Cheryl R. Blanchard?

The Form 3 shows that Cheryl R. Blanchard is a director of Xilio Therapeutics, Inc. It is an initial insider ownership report and, in this case, does not list any stock or derivative transactions.

Are there any share purchases or sales reported for Cheryl R. Blanchard at Xilio Therapeutics (XLO)?

No transactions are reported. The insider data show zero buys, zero sells, and no derivative exercises, gifts, tax withholdings, or restructurings for Cheryl R. Blanchard in this Form 3.

What role does Cheryl R. Blanchard hold at Xilio Therapeutics, Inc. (XLO)?

Cheryl R. Blanchard is identified as a director of Xilio Therapeutics, Inc. in the filing. She is not listed as an officer or a ten percent owner based on the provided insider data.

Does the XLO Form 3 filing indicate any derivative securities for Cheryl R. Blanchard?

No derivative securities are indicated. The derivativeSummary is empty and the transaction summary shows zero derivative transactions, meaning no options or similar instruments are reported in this filing.

What does the transaction summary in the Xilio Therapeutics (XLO) Form 3 indicate?

The transaction summary shows no activity: zero buys, sells, exercises, gifts, tax withholdings, or restructurings, and a neutral net buy/sell direction, reflecting an initial status-only insider filing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Blanchard Cheryl R

(Last) (First) (Middle)

828 WINTER STREET

SUITE 300

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026

3. Issuer Name and Ticker or Trading Symbol
Xilio Therapeutics, Inc. [ XLO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Elana Brockmann, Attorney-in-Fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)